Skip to content
approvedBone & Joint

Calcitonin

Also known as: Miacalcin, Fortical, Calcimar, Salmon Calcitonin, sCT, Calcitonin-Salmon

Calcitonin is a 32-amino acid peptide hormone naturally produced by thyroid C-cells that plays a central role in calcium and bone metabolism. The pharmaceutical form — salmon calcitonin (Miacalcin, Fortical) — is 40-50 times more potent than human calcitonin and has been FDA-approved since 1984 for the treatment of postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia of malignancy. Available as a nasal spray and injectable formulation, it inhibits osteoclast-mediated bone resorption and has notable analgesic properties for acute vertebral fractures.

3 cited references·5 researched benefits

Quick Answer

Calcitonin is a 32-amino acid bone-regulating hormone produced by thyroid C-cells. Salmon calcitonin (Miacalcin) is the FDA-approved pharmaceutical form, 40-50 times more potent than human calcitonin. It treats postmenopausal osteoporosis, Paget disease, and hypercalcemia by inhibiting osteoclast bone resorption. Available as a nasal spray or injection, it also provides analgesic benefit for acute vertebral compression fractures.

Key Facts

Mechanism
Calcitonin binds to the calcitonin receptor (CTR), a class B G-protein coupled receptor expressed on osteoclasts, renal tubular cells, and neurons. On osteoclasts, CTR activation triggers cAMP and PKC signaling that causes rapid cytoskeletal disruption — osteoclasts retract their ruffled borders and detach from bone surfaces, immediately inhibiting bone resorption. In the kidney, calcitonin reduces tubular reabsorption of calcium and phosphate, promoting their urinary excretion. The analgesic effect involves central mechanisms including stimulation of descending serotonergic pathways, beta-endorphin release, and direct CTR-mediated signaling in pain-processing regions of the CNS. Salmon calcitonin has higher receptor affinity and resistance to enzymatic degradation compared to human calcitonin, explaining its greater potency.
Research Status
approved
Half-Life
~1 hour (injectable); nasal bioavailability ~3-5%
Molecular Formula
C₁₄₅H₂₄₀N₄₄O₄₈S₂
Primary Use
Bone & Joint
Table of Contents

Benefits

  • Inhibits osteoclast-mediated bone resorption — FDA-approved for postmenopausal osteoporosis with demonstrated reduction in vertebral fracture riskstrong
  • Treats Paget disease of bone — reduces elevated serum alkaline phosphatase and bone pain in 50-70% of patientsstrong
  • Rapid correction of hypercalcemia — lowers serum calcium within 2-4 hours via renal excretion and osteoclast inhibitionstrong
  • Significant analgesic effect for acute vertebral compression fractures — reduces pain independent of anti-resorptive activity, often within daysstrong
  • Chondroprotective properties — preclinical and early clinical data suggest cartilage-preserving effects in osteoarthritis via MMP inhibitionpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intranasal spray (Miacalcin/Fortical)200 IUOnce daily, alternating nostrilsStandard dose for postmenopausal osteoporosis. Each actuation delivers 200 IU. Supplement with calcium (1000 mg) and vitamin D (400 IU) daily.
Subcutaneous or intramuscular injection100 IUOnce daily or every other dayUsed for Paget disease and hypercalcemia. For hypercalcemia: 4 IU/kg every 12 hours, may increase to 8 IU/kg every 6 hours. Subcutaneous preferred for self-administration.
Subcutaneous injection (acute fracture pain)100-200 IUOnce daily for 2-4 weeksOff-label use for analgesic effect in acute vertebral compression fractures. Some protocols use for 4-6 weeks with taper.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nasal irritation, rhinitis, and epistaxis — the most common side effects of nasal spray, occurring in 10-12% of patientscommon
  • Nausea and occasional vomiting — more common with injectable formulation, affecting 10-20% of patientscommon
  • Facial flushing — transient vasodilation affecting 2-5% of patients, particularly with injectioncommon
  • Injection site inflammation — local reactions at subcutaneous or intramuscular injection sitescommon
  • Possible increased malignancy risk — EMA issued a warning based on meta-analysis showing slightly increased cancer risk with long-term use; led to market withdrawal in some countriesserious
  • Allergic/anaphylactic reactions — rare but possible, especially with salmon-derived calcitonin; skin testing recommended for fish-allergic patientsserious

Frequently Asked Questions

Why is salmon calcitonin used instead of human calcitonin?
Salmon calcitonin is 40-50 times more potent than human calcitonin because it has higher binding affinity for the calcitonin receptor and is more resistant to enzymatic degradation. The salmon form has a different amino acid sequence that results in slower dissociation from the receptor and a longer duration of action. This increased potency means lower doses can be used, and it has been the standard pharmaceutical form since the 1970s. Recombinant human calcitonin has been developed but never achieved widespread clinical use due to the superior pharmacology of the salmon variant.
Is calcitonin still recommended for osteoporosis treatment?
Calcitonin has been largely superseded by more effective agents like bisphosphonates (alendronate, zoledronic acid), denosumab, teriparatide, and abaloparatide, which provide greater fracture risk reduction. Current guidelines generally reserve calcitonin for patients who cannot tolerate other osteoporosis therapies. However, calcitonin retains a unique niche for the analgesic management of acute vertebral compression fractures, where its pain-relieving effects provide benefit beyond bone density improvement. The European Medicines Agency restricted its use due to a small signal for increased cancer risk with long-term use.
How does calcitonin help with fracture pain?
Calcitonin has analgesic properties that are independent of its anti-resorptive effects. The mechanism involves central nervous system pathways: calcitonin receptors in the brain and spinal cord modulate pain signaling through stimulation of serotonergic descending inhibitory pathways, increased beta-endorphin release, and direct neuromodulation. In clinical trials, calcitonin nasal spray or injection reduced acute vertebral fracture pain significantly more than placebo, often allowing earlier mobilization. Pain relief typically begins within 1-2 weeks of treatment initiation.
What is the cancer risk concern with calcitonin?
A 2012 meta-analysis by the EMA found a small but statistically significant increase in the risk of malignancies (particularly prostate cancer, hepatocellular carcinoma, and basal cell carcinoma) in patients treated with calcitonin versus placebo — with an overall cancer incidence of 4.1% vs 2.9%. This led the EMA to recommend limiting calcitonin use to short courses and withdrawing the nasal spray. The FDA maintained approval but added warnings. The absolute risk increase is small, but the finding shifted calcitonin from a first-line to a last-resort osteoporosis therapy.

References

  1. 1
    Calcitonin for the treatment and prevention of osteoporotic fractures in post-menopausal women(2000)PubMed ↗
  2. 2
    Benefit-risk assessment of calcitonin for the treatment of osteoporosis and cancer risk(2012)PubMed ↗
  3. 3
    Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study(1997)PubMed ↗

Latest Research

Last updated: 2026-02-19